Halozyme Therapeutics, Inc. (HALO)

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

As of November 3, 2026, Halozyme Therapeutics, Inc. (HALO) stock rose to $130.87, up 1.49% (+$1.92) versus the previous close. On the day, shares have traded between $128.25 and $131.36. That puts HALO near the top of its 52-week range of $61.23 to $134.00. Halozyme Therapeutics, Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $14.86 billion, with about 274.8K shares changing hands.

Latest HALO news

• HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Yahoo Finance· Oct 30, 8:36 AM ET
• Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Yahoo Finance· Oct 29, 1:18 PM ETEXEL
• Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthYahoo Finance· Oct 29, 9:00 AM ET
• What Did Halozyme Stock Investors Miss Before The Run?trefis.com· Oct 28, 5:24 AM ET
• Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumYahoo Finance· Oct 27, 7:32 AM ET
• TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataYahoo Finance· Oct 26, 10:41 AM ET
• Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyYahoo Finance· Oct 26, 10:25 AM ET
• RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallYahoo Finance· Oct 26, 10:17 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want HALO headlines, alerts and AI research in one place? Create a free account →

• $HALO The Hague decision will have implications for all Alteogen partnered priducts, not just Keytruda. https://www.asiae.co.kr/en/article/2026101117262634657

  @Sean29md· Nov 2, 8:09 AM ET

• $HALO More sold 133.90

  @WAJeff· Oct 30, 10:48 AM ET

• @JasonCO @Tommojg @Jblack500 @WAJeff @cynicaloptimist @BustaCapital @IsabellaDC @No_Face_character Putting on da $HALO as fugly shoe$ are in style $LLY can help with $LFST $TGTX - LFG

  @MaverikIT· Oct 30, 9:56 AM ET

• $HALO Important to distinguish the Munich Regional Court from the German Federal Patent Court. The latter also issued a preliminary opinion favorable to Halozyme on the validity of EP 2 797 622. The most important source is actually the October 7, 2026 judgment of the District…

  @Sean29md· Oct 30, 9:42 AM ET

• $HALO https://www.pinsentmasons.com/out-law/news/dutch-patent-injunction-extends-across-eight-european-countries

  @Sean29md· Oct 30, 9:20 AM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →